<DOC>
	<DOC>NCT00288925</DOC>
	<brief_summary>To evaluate the safety of two doses of Z-360 with Gemcitabine administration for subjects with unresectable advanced pancreatic cancer in order to determine the optimal dosage for PhaseII study</brief_summary>
	<brief_title>Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Subjects with unresectable locally advanced or metastatic pancreatic cancer KPS &gt; 70% Life expectancy of at least 3 months received previous chemotherapy for the current indication received previous radiotherapy for the current indication Currently receiving chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>